ONCAlert | 2017 San Antonio Breast Cancer Symposium

Choosing Between TAS-102 and Regorafenib in Colorectal Cancer

Cathy Eng, MD, FACP
Published Online:10:03 AM, Thu November 30, 2017

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.